BPC-157

BPC-157 is a synthetic chain of fifteen amino acids — GEPPPGKPADDAGLV — reproducing a partial sequence of Body Protection Compound, a protein first characterised in gastric juice. The parent protein is what gives the fragment its name, and the digestive origin is not incidental: it is the reason the sequence tolerates conditions that degrade most peptides.

That stability is the practical reason BPC-157 became so heavily published. A peptide that survives in aqueous solution and in an acidic environment can be dosed in animal studies by routes that are closed to more fragile molecules, which widened the range of experiments it could appear in.

The literature is concentrated on three signalling questions rather than on one outcome:

• Angiogenic signalling. Interaction with the VEGFR2 pathway, and the formation of new vasculature in injured tissue, is the most reported single finding.

• Fibroblast behaviour. Migration and collagen organisation within healing connective tissue, measured as tensile strength and fibre alignment in excised tissue.

• Nitric oxide systems. Modulation of NO pathways, which is the thread linking the vascular findings to the gastrointestinal ones.

• Growth factor receptor expression. Changes in receptor density at the site of an experimental lesion.

BPC-157 is studied in rodent models of Achilles and other tendon transection, ligament injury, muscle crush and transection, and a well-developed body of gastrointestinal work covering experimental ulceration, inflammatory bowel models and anastomotic healing. Vascular and neurological models appear less often but are established.

Researchers generally select it where a locally confined effect is wanted and where a compound has to survive the experimental route of administration. Those two properties, rather than any single result, are what keep it in use as a comparator.

TB-500 is the usual counterpart. The two are studied together often enough that the pairing has its own literature: TB-500 distributes systemically through actin binding, BPC-157 is examined for activity at the site it is applied to, and the comparison between them is frequently the point of the experiment.

That pairing is the basis of the Wolverine Stack, and BPC-157 also appears in the KLOW Stack alongside copper-binding and anti-inflammatory sequences.